RxDoctor Payments Data

Nicole Herpick

Family · Bel Air, MDNPI 1770132391

Payments from drug & device makers

$4,980in general payments, 2019–2025

Across 180 payments — averaging $27.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$754
  • AbbVie$662
  • Astellas Pharma US Inc$653
  • Esperion Therapeutics, Inc.$471
  • Bayer$315
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,65293%
  • Education$3287%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,980 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$94,533
MounjaroTirzepatide34$43,659
RybelsusSemaglutide18$24,897
JardianceEmpagliflozin19$18,715
FarxigaDapagliflozin Propanediol13$18,022
MyrbetriqMirabegron11$14,933
QuliptaAtogepant11$12,087
LinzessLinaclotide11$7,983
Tresiba Flextouch U-100Insulin Degludec12$5,642
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$4,457
Incruse ElliptaUmeclidinium Bromide12$4,178
Atorvastatin Calcium186$2,922
Albuterol Sulfate HfaAlbuterol Sulfate46$2,453
Rosuvastatin Calcium56$2,056
Levothyroxine Sodium137$1,741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$150$119,43094 claims
Lilly USA, LLCMounjaro$62$43,65934 claims
AbbVieQulipta, Linzess$662$20,07022 claims
AstraZenecaFarxiga$754$18,02213 claims
Astellas Pharma US IncMyrbetriq$653$14,93311 claims
GSKIncruse Ellipta$20$4,17812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.

Other family in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →